AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with an undisclosed leading global pharmaceutical company to generate novel antibody therapeutics to a specified disease target. This is the third collaboration with a leading pharmaceutical company announced by AnaptysBio during 2010.
“AnaptysBio has taken full advantage of this knowledge to create a powerful, next generation platform with distinct technical advantages for generating therapeutically useful antibodies.”
Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) technology platform. The pharmaceutical company will receive worldwide rights to develop and commercialize antibodies generated by AnaptysBio. AnaptysBio receives an upfront sum and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.
“SHM is recognized as the key mechanism for the natural evolution and optimization of antibodies in the immune system,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “AnaptysBio has taken full advantage of this knowledge to create a powerful, next generation platform with distinct technical advantages for generating therapeutically useful antibodies.”
Novel antibodies show promise for tumor targeting and RAD51 inhibition